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Abstract
Background: SFTS virus (SFTSV) is a newly discovered pathogen to cause severe fever with thrombocytopenia syndrome
(SFTS) in human. Successful control of SFTSV epidemic requires better understanding of the antigen target in humoral
immune responses to the new bunyavirus infection.
Methodology/Principal Findings: We have generated a combinatorial Fab antibody phage library from two SFTS patients
recovered from SFTSV infection. To date, 94 unique human antibodies have been generated and characterized from over
1200 Fab antibody clones obtained by screening the library with SFTS purified virions. All those monoclonal antibodies
(MAbs) recognized the nucleocapsid (N) protein of SFTSV while none of them were reactive to the viral glycoproteins Gn or
Gc. Furthermore, over screening 1000 mouse monoclonal antibody clones derived from SFTSV virions immunization, 462
clones reacted with N protein, while only 16 clones were reactive to glycoprotein. Furthermore, epitope mapping of SFTSV
N protein was performed through molecular simulation, site mutation and competitive ELISA, and we found that at least 4
distinct antigenic epitopes within N protein were recognized by those human and mouse MAbs, in particular mutation of
Glu10 to Ala10 abolished or significantly reduced the binding activity of nearly most SFTS patients derived MAbs.
Conclusions/Significance: The large number of human recombinant MAbs derived from SFTS patients recognized the viral
N protein indicated the important role of the N protein in humoral responses to SFTSV infection, and the critical epitopes we
defined in this study provided molecular basis for detection and diagnosis of SFTSV infection.
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Introduction
Severe fever with thrombocytopenia syndrome (SFTS), with
average case fatality rate of 12%, is an emerging infectious disease
caused by a newly discovered virus, named SFTS virus (SFTSV)
[1]. Although the disease has been proved to have viremia in acute
phase and the specific antibody responses were appeared in both
acute and convalescent phases of SFTS [1,2], however, the
functions of viral structural proteins in immune responses and
immune pathogenesis still remain unclear.
SFTSV was classified in the genus Phlebovirus, family
Bunyaviridae, a family of spherical enveloped virus with a
tripartite RNA genome of negative or ambisense polarity [3].
Like other known Bunyavirus, SFTSV contains three structural
proteins, RNA-dependent RNA polymerase (L), glycoproteins
(Gn and Gc), and nucleocapsid(N)proteins. The N protein of
245 amino acids, as in the case of many other nucleoproteins of
negative strand RNA virus, acts as a scaffold for packing of
virus. Antibodies against SFTSV N protein were commonly
detected early after infection, which suggested the N protein is
possible to be used as target antigen for early diagnosis of
SFTSV infection. It has been reported that the viral N protein
is highly immunogenic for many members in the genus of
Phlebovirus and acts as major antigen [4,5]. Therefore, major
epitopes of the SFTSV N antigen and related functional
significance need more investigation.
In this report, we for the first time described the generation
and characterization of a panel of human monoclonal
antibodies (MAbs) against SFTSV N protein using phage
display library approach, and the targeted antigenic epitopes
were further mapped by competitive assay, molecular modeling
and site-directed mutations. The results provided in this study
could facilitate understanding of humoral responses to SFTSV
infection and help to develop diagnostic tools for detection and
diagnosis of SFTSV infection at various infection stages, which
could be ultimately applied in clinical work as well as epidemic
surveillance.
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Cells, Virus and Purified Virions
The origin and preparation of SFTSV have been described
earlier [1]. Briefly, Vero-E6 cells (ATCC CRL-1586) were infected
with SFTSV strain HB29 [1] at m.o.i. of 1 and cultivated for 14
days. The medium supernatant containing virus particles of
1.0610
8/ml was harvested and removed of cell debris by
centrifugation, and further purified using ultracentrifugation with
20% sucrose density gradient. The purified virions were analyzed
by SDS-PAGE and electron microscope analysis to confirm the
quality of virus particles, and further used as antigen for phage
library screening or antibody analysis.
Construction and Screening of Human Antibody Phage
Display Library
The procedures of phage display library in the vector pComb
3H followed the methods described previously [6,7,8]. Briefly,
lymphocytes were isolated from the blood samples of two SFTS
patients in convalescent phase, from Shandong province of China.
Total cellular mRNA was extracted using RNeasy Mini kit
(Qiagen, Valencia, CA) and cDNA was synthesized with primer
oligo (dT) using Transcriptor High Fidelity cDNA Synthesis kit
(Roche, Mannheim, Germany). PCR amplification was then
performed using FastStrat High Fidelity PCR System (Roche,
Mannheim, Germany). The light and heavy chain genes were
amplified from the cDNA by PCR using the primer pairs from 5
VK, 7 V L and, 8 VH gene family [9]. The light chain genes were
first cloned into the vector pComb 3H with enzymes Xba I and Sac
I, therefore the heavy chain genes were cloned in to the light chain
library pool with enzymes Xho I and Spe I as standard protocol
published previously [8,9]. The initial diversity of the library was
evaluated and assured by sequencing of randomly picked over 200
clones for each step of library construction and the complexity of
library was then calculated. The final yielded antibody libraries
were panned and screened with purified SFTSV virions following
the standard panning procedure [10].
Generation of Human IgG Antibody or Mouse
Monoclonal Antibody
After three rounds of phage panning, individual clones from
enriched phage pools were analyzed by ELISA against SFTS
virions or purified N protein. The positive human Fab clones were
sequenced and aligned with the DNAPLOT program for
alignment to the VBASE database. The human Fab antibodies
selected based on binding activity and sequence variance were
converted to human IgG by cloning the Fab genes into baculovirus
expression cassette vectors, expressed in SF9 cells, and finally
purified with protein A column (GE Healthcare, Sweden) for
further characterization and functional analysis. Rabbit polyclonal
and mouse monoclonal antibodies against N protein were
produced commercially by AbMax Biotechnology company
(China). The protocols for animal tests were reviewed and
approved by animal care committee of China CDC.
Production and Purification of Recombinant N Protein
The N protein gene from S segment of SFTSV strain HB29
with His tag was cloned into vector pET30a (Novagen, Madison,
USA) and expressed in Escherichia coli as we described previously
[11]. Briefly, the E.coli bacteria (Rosetta2 DE3) transfected with N
expression vector plasmid was induced in the presence of 1 mM
isopropyl-1-D-thiogalactopyranoside (IPTG), followed by growth
at 30uC for 16 h. The protein was obtained from inclusion bodies
and purified on an AKTA prime plus system equipped with
HisTrap HP column (GE Healthcare, Sweden) for affinity
chromatography, and the N protein was eluted at a gradient
from 100 to 300 mM imidazole and finally dialyzed with PBS
buffer (pH 7. 2). The purity of the protein was confirmed by SDS-
PAGE and western blot analysis using SFTS patient sera. The
purified N protein then further used for epitope mapping in the
study.
Immunofluorescence Assay (IFA)
IFA was performed on different cells according to the
experimental design. Vero-E6 cells infected with SFTSV were
used to measure the reactivity of MAbs for viral antigens. The
SFTSV N protein or glycoprotein (Gn and Gc) genes were
separately cloned into baculovirus vector pAc-UW51 and
expressed with recombinant baculovirus/SF9 (ATCC CRL-
1711) cells system, the expression of N protein or glycoprotein
was confirmed by SFTS patient sera. The N protein or
Glycoprotein expressing SF9 cells were used to determine the
viral protein binding specificity of human or mouse monoclonal
antibodies gained in this study. To measure the binding activity of
site-directed mutations, 293T cells were grown to 80%–90%
confluence and transfected with pCDNA-N plasmid, using the
FuGene reagent (Roche). The cells were washed and fixed on glass
slides with acetone. Human or mouse MAbs were incubated for
30 min at 37uC, and bound antibodies were detected by FITC-
conjugated goat anti-human or anti-mouse antibody (Sigma), and
visualized under immunofluorescence microscope.
Western Blot Analysis (WB)
The viral proteins from purified SFTS virions were separated by
SDS-PAGE under reducing conditions, and transferred to a
PVDF membrane. After blocking with PBST (0.01 M PBS with
0.1% Tween-20, pH 7.4) containing 1% BSA for 1 h at room
temperature, the membrane-immobilized proteins were probed by
purified human MAbs (20 mg/ml) or 1:50 diluted mouse MAbs
from hybridoma ascites overnight at 4uC. Monoclonal goat anti-
human or anti-mouse antibody (Sigma) was used as secondary
antibody. The bands were visualized by 3, 39 diaminobenzidine
(DAB) according to the manufacturer’s instructions.
Microneutralization Assay
The microneutralization assay was performed as previously
described [1]. Briefly, 2-fold serial dilutions of the 1:10 diluted
human MAbs (1 mg/ml) or mouse MAbs from hybridoma ascites
were incubated with a suspension of 100 TCID50 of SFTSV strain
HB29 for 1.5 hours. The mixture was then incubated with Vero
cells in quadruplicate in a 96-well plate for 12 days. Viral infection
was detected using immunofluorescence assays with rabbit
polyclonal antibody against N protein. The end-point titer was
expressed as the reciprocal of the highest dilution factor that
prevented infection.
Competitive ELISA Assay
A panel of extensive competition experiments was developed to
evaluate the binding specificity of MAbs and determine whether
these MAbs bind to distinct sites in N protein. Purified SFTSV N
protein was used as coating antigen in 0.05 M bicarbonate buffer
(pH 9.6) and incubated overnight at 4uC. After blocking the plate
with PBST containing 1% BSA for 1 h at 37uC, human or mouse
MAbs were dissolved in PBS and added into each well by 50 mli n
continuous series 2-fold dilution to prepare a concentration
gradient of competitors. Then 50 ml HRP-MAbs was then added
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90% of the maximum absorbance value on N antigen. After
incubation, 3, 39,3 ,5 9 -tetramethylbenzidine (TMB) was added,
and absorbance was measured at 450 nm. Percent of binding
inhibition of labeled antibodies was calculated according to the
formula:
f ~
A450 uninhibited ðÞ {A450 inhibited ðÞ
A450 uninhibited ðÞ
  100%
Molecular Modeling and Docking of the Antibody to
N Protein
The computational simulation was carried out using Discovery
studio 2.0 (Accelrys, San Diego, CA) [12,13,14]. Suitable template
was obtained through a BLAST search of the Protein Databank
(PDB). The homology modeling of human antibody and SFTSV
N protein were performed individually using DS Homology
Modeling protocol, and the 3D model of antibody was optimized
using Antibody loop refinement protocol. The N protein and
antibody were further refined by Energy Minimization and
Molecular Dynamic Simulation program under CHARMm
forcefield, which provides powerful mechanics for studying the
energetic and motion of molecules. The models were validated by
Ramachandran plots. Protein-protein docking of N protein with
human monoclonal antibody was performed using the ZDOCK
and RDOCK program by specifying the antibody residues of the
variable region on the binding interface. RDOCK refinement was
performed on the top 100 poses of the filtered ZDOCK output,
and applied scoring function to each docked structure for best
binding models. By visualizing and analyzing the 3D computa-
tional interaction, several potential interfaces of the N protein were
chosen in further study.
Amino Acid Substitutions by Site-directed Mutagenesis
A set of site-specific mutations were generated using Quick-
Change II site-directed mutagenesis kit (stratagene, La Jolla, CA)
for PCR using manufacturer’s guidelines. The truncation muta-
tions of N protein were generated from the N-terminal or C-
terminal end by every 5 amino acids. All mutations were generated
using pCDNA5.0 plasmid as a template. All constructs were
transfected to 293T cells for transient expression, and the
mutations were analyzed by IFA assay described above for
binding activity with human and mouse MAbs.
Ethical Consideration
According to the medical research regulation of Ministry of
Health, all studies involved in human samples were reviewed and
approved by the ethics committee of China CDC, which uses
international guidelines to ensure confidentiality, anonymity, and
informed consent. The written informed consent was agreed by
the patients. The protocols for animal tests have been approved by
animal care committee of China CDC.
Results
Generation and Characterization of Human Antibodies
Against SFTSV
Using the pComb 3H vector system, the SFTSV patients
derived light chain library was first constructed with a complexity
of .1.0610
7 clones, the Fd heavy chain genes were efficiently
inserted into the light library vectors and finally resulted in a initial
combinatorial Fab library with a complexity of .1.0610
8
independent clones and 100% Fab genes diversity after sequencing
confirmation. After three rounds of phage panning against purified
SFTS virions, we selected more than 1200 Fab clones, of which
475 clones showed positive reaction to SFTS virions. However, all
475 clones were only reactive to the purified N protein tested by
ELISA and IFA. To select human antibodies to SFTSV
glycoproteins, we used purified N protein as blockage in another
process of phage panning. However, no targeted Fab antibodies
against glycoproteins were identified over screened additional 600
Fab clones. In addition to these human recombinant monoclonal
antibodies, through screening 1000 mouse MAbs clones derived
from immunization with SFTSV virions, 462 clones were
identified to react with N protein, while only 16 clones were
reactive to glycoprotein Gn or Gc expressed in recombinant
baculovirus transfected SF9 cells (Figure S1).
Sequence analysis of all 475 human positive Fab clones revealed
the presence of 94 unique ones. Using the DNAPLOT program
for alignment to the VBASE database [15], the germ line and gene
families of these isolated Fab antibodies were identified. The heavy
chain genes of all 94 positive clones belonged to VH3 family, while
82 of these positive clones were of VK1 family and the rest
possessed distinct VK3, VL1, VL2 and VL3 families (Figure 1). As
shown in Table 1, 45 unique sequences in complementarity
determining regions (CDRs) of heavy chain were aligned from the
94 unique heavy and light chain combinations. Overall, CDR1
and CDR2 have less sequence variation, in contrast, CDR3 shows
the greatest variability. The high frequency of V-D-J recombina-
tion and amino acid diversification found in CDR3 region might
represent the process known as affinity maturation in vivo,
suggesting that N protein was a highly immunogenic antigen in
humoral immune responses to the SFTSV infection.
Next, above N protein specific Fab antibody clones with unique
sequences were selected and converted into IgG molecules based
on their sequence diversity and specific N protein binding activity
(Figure 2A). 20 human IgG antibodies and 11 mouse MAbs to the
N protein were further analyzed by western blot analysis. We
found that 16 selected human MAbs and all 11 mouse MAbs were
reactive to the denatured N protein of SFTSV, and showed a
positive protein band of 27 KDa in western blot assay as presented
in figure 2B with 5 human antibodies (H2A12, H2A4, H2E4,
H2F4 and H1C2) and 3 mouse MAbs (M7E11, M3E11 and
M1D8), while 4 human MAbs including H2H9, H4B9, H4C8 and
H4E11 did not appear the positive binding. The different binding
properties of above human and mouse MAbs in western blot assay
indicated the antibodies recognized either linear epitope or
conformational epitope in the SFTSV N protein. However, none
of the N protein specific antibodies had the neutralizing activities.
In contrast, 9 of 16 mouse MAbs targeted to SFTSV glycoprotein
Gn or Gc showed significant neutralizing activities at various
levels, and none of them reacted with denatured viral antigen in
western blot assay (Table S1).
Competitive ELISA Assay of Monoclonal Antibodies
Against N Protein
In order to characterize epitope binding patterns of the 20
human MAbs and 11 mouse MAbs with SFTSV N protein, a set
of competitive ELISA experiments were performed. Based on
above analysis data, we chose three human MAb H2A12,
H2H9,H3E11 and one mouse MAb M1D8 as detective antibody
labeled with horseradish peroxidase (HRP), and totally 20 human
MAbs and 11 mouse MAbs were used as competing antibodies in
the test. As shown in Table 2, except H2H9, all human MAbs
Monoclonal Antibody to SFTSV
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chains genes of Fab antibodies. The phylogenetic tree was based
on amino acid sequence in the variable regions of light chains. Among
the 94 human Fab clones, 82 clones in purple represent human
germline genes as specified by the VK1 family, 2 belong to VK3 family, 4
belong to VL1 family, 1 belongs to VL2 family, and 5 belong to VL3
family.
doi:10.1371/journal.pone.0038291.g001
Table 1. Amino acid sequences of the complementarity
determining regions (CDRs) in 45 unique heavy chains of
human Fab clones isolated from phage antibody library.
Fab clones
b CDR1 CDR2 CDR3
H2A12
a SYSMN SISSSSSYIYYADSVKG EDYGL*****LDY
H2B10
a ----- ----------------- -T---*****---
H2A1 ----- ----------------- -S--P*****---
H4G1 ----S -----R----------- -T---*****---
H2D3 ----- ----G------------ -S--P*****I--
H2F8
a ----- ----GGN---------- -S--P*****---
H4D9 ----- ----R------------ -T--P*****---
H4B7 ----- ----G------------ -L--N*****---
H4A4
a ----- ----G------------ DS-H-*****F--
H2B8
a ----- ----G------------ DL--P*****---
H2C11
a ----- ----G------------ DS--V*****-G-
H4C1 ----- ----G------------ DN--I*****F--
H2C2 ----- ----G------------ D---V*****S-V
H2C10
a ----- ----R------------ DN--I*****F--
H4A6 T---- ----R------------ DN-A-*****M-V
H4E12 ----- ----N------------ DS--P*****--V
H4E5 ----- F---------------- DT--I*****F--
H4B2 ----- ----------------- D----*****I--
H2D7 ----S ----------------- D---V*****-H-
H2F10
a ----- ----------------- D---S*****-SA
H2D12
a ----- ----------------- DN--I*****F--
H4F7
a ----- ----------------- DS---*****F--
H4G5 ----- ----------------- DN---*****F--
H2A8
a ----- ----------------- DQ--V*****I--
H4E3 ----- ----------------- DL--V*****V-I
H4A7 ----- ----------------- -N--V*****I--
H2B4 ----- ----------------- -----*****M-V
H2B1
a ----- ----------------- -N---*****M-V
H2A6 ----- ----------------- DS--I*****M-V
H2F5 ----- ----------------- DS--F*****M-V
H4G4 ----- ----------------- ----V*****-YV
H2A4
a ----- ----------------- D---I*****S--
H4C9 ----- ----G------------ RN--E****YS--
H4B3 ----- ----G------------ TPG-IAVAEFM-V
H1C2
a ----- ----------------- TPG-IAVAEFM-V
H2D1 T---- ----------------- TPG-IAVAEFM-V
H4C8
a ----- ----------------- HFV-ASTH**T--
H2E4
a ----- ----------------- GHV-ATD***---
H2F4
a T---- ----------------- D---VIR***F-P
H4E11
a -S--- ----GG----------- GGEYSSG***F--
H5D12 ----- ----G------------ LAA-ASSS**I--
H4B9
a ----- ----G------------ TPG-GDYYY*M-V
H5A2 ----- ----------------- DL-YGDYV**---
H2H9
a ----- ----------------- VT-YGSGSYFF--
H5D7 --W-H R-YTDG-STS------- GSSYYG****M-V
aMAbs labeled were included in further study;
b: MAbs derived from SFTS
patients were designated as ‘‘H’’ for the first letter, and mouse derived MAbs
were designated as ‘‘M’’ for the first letter; -: Indiated the identical to the amino
acid sequence of Fab H2A12; *: No amid acid.
doi:10.1371/journal.pone.0038291.t001
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H2A12, including human MAbs H4B9, H4C8 and H4E11, which
were potential conformational epitope binder as shown in the WB
assay. Further, competition of mouse MAbs with H2A12 also
showed that 9 of the 11 mouse MAbs, represented by M7E11,
obviously blocked the binding activity with human MAbs H2A12.
However, 2 mouse MAbs M3E11 and M1D8 did not block the
binding of H2A12, indicating that the N protein epitopes
recognized by the two mouse MAbs were probably different from
the epitope recognized by human MAb H2A12. Furthermore, we
selected above 3 MAbs H2H9, M3E11 and M1D8 which were
non-competitive with H2A12 as detective antibodies to determine
the binding competition of each of the 3 MAbs with all human and
mouse MAbs. As showed in Table 2, none of the 3 MAbs showed
competition with other MAbs. Thus, there were at least 4 distinct
binding sites in N protein, represented by the MAbs of H2A12,
M3E11, M1D8 and H2H9, and the epitope of MAbs H2A12 was
the major binding site of N protein for most human and mouse
MAbs.
Computer Modeling and Docking of Interaction between
Antibody and N Protein
Since the epitope recognized by a panel of MAbs represented by
H2A12 might be a dominant epitope of SFTSV N protein, we
further define potential epitopes on N protein surface recognized
by H2A12. We first found an antibody crystal structure 1DFB
(PDB) which has as high as 90% sequence similarity with human
Figure 2. Characterization of human and mouse MAbs to SFTSV N protein. A) IFA analysis shows all selected MAbs are reactive to the viral
and recombinant N protein. Vero: Vero cells infected by SFTSV strain HB29; Sf9: Sf9 cells expressing recombinant N protein with the baculovirus
system; 293T: 293T cells transiently expressing the recombinant N protein. B) Western blot assay of human and mouse MAbs. Most MAbs represented
a positive N protein band at 27 KDa, while MAbs H4B9, H4C8, H4E11 and H2H9 showed negative result. R. poly: rabbit polyclonal antibody
immunized with the SFTSV N protein.
doi:10.1371/journal.pone.0038291.g002
Table 2. Competitive ELISA assay of monoclonal antibodies
against N protein.
MAbs
a HRP conjugated MAb (%)
b
H2A12 H2H9 H3E11 M1D8
H2A12 93 22 25 12
H2A4 75 16 17 21
H2E4 80 22 27 31
H2F4 77 19 22 25
H1C2 78 24 23 14
H4B9 80 22 31 11
H4C8 82 27 17 12
H4E11 80 31 13 11
H2H9 32 88 19 12
M7E11 88 30 15 32
M3E11 20 15 85 19
M1D8 20 23 14 90
aCompeting MAbs, SFTS patients derived were designated as ‘‘H’’ for the first
letter; and mouse derived were designated as ‘‘M’’ for the first letter.
bPercentage of binding inhibition of HRP conjugated detective antibodies in
competitive ELISA assay.
doi:10.1371/journal.pone.0038291.t002
Monoclonal Antibody to SFTSV
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simulation. The crystal structure of N protein of the rift valley
fever virus (RVFV) was selected as model for SFTSV N protein,
because RVFV N protein has maximal identity of 41.4% in
backbone structures with SFTSV N protein [1], and more
importantly, they both belong to the genus Phlebovirus in the
Bunyaviridae family with similar structure [16]. After using Energy
minimization and molecular dynamic optimization to optimize the
structure, we used DOCK program for geometric docking
simulation to mimic the possible interaction of the antibody and
N protein models. Computer-simulation predicted fragments of
amino acids 8–15, 35–45, 74–89, 113–116, 132–142, and 217–
222 in N protein, which had highest scores as key contact sites by
the RDOCK program, as possible binding sites of antibody
(Figure 3). The amino acids selected by computer-simulation were
further confirmed using site-directed mutagenesis in vitro to
validate the predicted epitopes in real protein-protein interaction
between SFTSV N protein and human MAbs.
Epitope Mapping by Site-directed Mutations
Since previous studies on Hantavirus, RVFV and Uukuniemi virus
(UUKV) showed that terminal regions of viral N protein are
especially important for its function [16,17,18], we tested the both
N and C terminal truncated protein first. We found that the N
protein with truncation of 5 amino acid at N terminus (DN5) was
recognized by all tested antibodies listed in Table 3, while the
antibody binding activity of the N protein with truncation of 10
amino acid at N terminus (DN10 ) or 5 amino acid at C terminus
(DC5) was significantly declined in IFA tested with the N protein
specific rabbit polyclonal antibody (Table 3), and even abolished
tested with those human or mouse MAbs. However, the binding
activity of DN10 or DC5 with rabbit polyclonal antibodies was
remained in western-blot assay (Figure S2).
In order to address which amino acid sites were critical for
MAbs binding and the antigenic epitopes of N protein, single
mutations with alanine substitution were performed. For N
terminus, single alanine mutations of N terminal 5,15 amino
acid resulted in no change of antibody binding activities, but only
the mutation of Glu10 to Ala (E10A) significantly reduced the
binding activity of most human MAbs represented by H2A12, and
most mouse MAbs represented by M7E11 (Table 3). The
mutation of E10A combining with mutation of Phe11 to Ala
(F11A) resulted in the complete loss of binding with those MAbs,
while single mutation of F11A had no obvious reduction in
binding activity to above MAbs. Mutation analysis of C-terminal
fragment 235,245 showed that only mouse MAbs M3E11
showed no binding activity to the single mutation of Arg243 to
Ala (R243A), while the binding activity of rest antibodies was not
affected. Further, based on predicted antibody binding sites from
computer modeling, we did single mutations on all 6 amino acids
fragments identified. The results showed that, at amino acid
positions 38,45, substitution of Lys40 to Ala (K40A), Lys41 to Ala
(K41A) and Glu44 to Ala (E44A) were indispensible to the binding
of mouse MAbs M1D8, while not affected binding with all other
MAbs (Table 3). The mutation analysis of amino acid 132,142
showed that mutation of Tyr140 to Ala (Y140A) generally reduced
the binding activity of all tested antibodies including polyclonal
antibody. Alanine mutations in amino acid 74–89, 113–116 and
217–222 showed no reduction in the binding activity with all
MAbs. Therefore, the critical amino acids in epitopes of the N
protein for antibody binding are listed in the modeling structure
(Figure 4A), and Ramachandran plot of the SFTSV N protein
model illustrated that visualized backbone dihedral angles of
amino acid residues were properly validated (Figure 4B). However,
all above single mutations did not reduce any binding activities of
human antibodies H1C2 and H2H9, and the latter one was
suspected to have an independent binding site different from
others according to the competition ELISA assay (Table 2).
Discussion
In this study, we for the first time reported the generation and
characterization of a panel of human MAbs by using phage display
technology. The critical role of N-terminal amino acids for the
Figure 3. Design for single mutations of SFTSV-N protein. Computer-simulated docking structure shows 3 representative binding sites on N
protein at A) amino acid 8–15, B) amino acid 35–45, and C) amino acid 132–142. D) The scheme represents the regions of site-directed mutations in N
protein based on 3D-structure predictions and truncation studies.
doi:10.1371/journal.pone.0038291.g003
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sites were finally defined.
As a newly emerged viral pathogen, successful control of
SFTSV epidemic requires a better understanding of antigen
targets in humoral immune responses to the infection. Results in
this paper presented that intensive antibodies were reactive to the
N protein, but less antibodies to viral glycoprotein, which is
believed to be major neutralizing antibody inducer. In general, all
virus infection should induce neutralizing antibodies, as for
bunyavirus infection, it has been largely evidenced that almost
all of neutralizing polyclonal or monoclonal antibodies are viral
glycoprotein Gn or Gc specific [19,20], but not for N protein
specific antibodies, even the antibodies to some strong immuno-
genic N protein epitopes had no neutralizing activity [5,21]. The
large numbers of human antibodies derived from SFTS patient
antibody phage display library finally turn out to the N protein, it
is possible that the abundant amount and high immunogenicity of
the N protein produced large amount of antibodies with high
binding affinity to N protein distract the selection of neutralizing
antibodies to glycoprotein in the phage panning process, as for
other Bunyavidridae such as RVFV and Puumala virus, it has been
reported that the reaction between antibody and glycoprotein
involves conformational epitopes that are more fragile [5,22,23].
In addition, the SFTS virions we used for antibody library
screening might not be sufficiently native in the process of phage
panning. The undergoing effort for purifying native glycoprotein
would facilitate identifying MAbs against glycoprotein.
However, the large number of specific antibodies against
SFTSV N protein gained in this study also indicated that the N
protein played an important role in humoral immune responses to
the new bunyavirus infection and the process of affinity
maturation in vivo after infection aggravated the inducing of
numerous antibodies. These data are coincident with previous
reports from other members in Phlebovirus genus, family Bunyavir-
idae. For members in Phlebovirus genus, the N protein is the most
abundant viral product in virions and virus infected cells [3]. It is
reported that the N protein of RVFV was reported to be the
immunodominant viral protein, and antibodies against N were
readily detected early after infection and in convalescent
individuals, providing robust basis for diagnostic detection of the
disease [4,24,25]. Also, the nucleoprotein of Toscana virus was
identified as the major antigen responsible for both IgM and IgG
in Toscana virus infected patients by immunoblotting and
semiquantitative radioimmunoprecipitation assays [5]. Although
it is generally agreed that the N proteins of the bunyaviruses dose
not induce neutralizing antibodies, even antibodies to the strongly
immunogenic N protein of RVFV had no neutralizing activity
[26,27], protection studies conducted in vivo demonstrated that
monoclonal antibodies to the N protein partially protect animals
from challenge with the virulent virus [5,21]. Similar results have
been obtained in Hantavirus infections where antibodies to the N
protein have been shown to protect mice but no neutralizing
activities in vitro [28,29]. We also tested more than 20 human
MAbs and none of them had neutralizing function. Although the
exact role of various MAbs induced by the SFTSV N protein is not
clear, at least, we consider that the N protein induced intense
specific antibody responses, and served as an important antigenic
target for diagnosis of SFTS.
As an emerging infectious disease, epitopes in the N protein of
SFTSV has not been identified. In fact, there were few reports on
epitopes of viral N proteins even for other members in the
Phlebovirus genus of Bunyaviridae family. It was reported that at least
three different epitopes of RVFV N protein were defined through
competition ELISA assay, and the amino acid residue 159 might
be an important residue for antibody binding [4]. In this study, we
found that the amino acids at positions N10, N11 of N-terminus
and C243 of C-terminus were significantly needed for keeping the
immunogenicity of SFTSV N protein. In fact, the N- and C-
terminus are reported to be important for oligomerization and
stabilization of N protein of Phlebovirus. The oligomerization of N
monomers is an essential requirement for RNA packing in mature
particles. The polymer of N protein can provide adequate
templates for RNA binding, and contribute to the formation of
inclusion body in the cytoplasm of virus infected cells [17,30]. The
oligomerization of UUKV N protein depends on the presence of
intact helices on both termini of the N protein molecule and that a
specific structure in N-terminal region plays a crucial role in the N-
N interaction [18]. The N terminal amino acids 1 to 70 of RVFV
are also involved in the dimmer formation as reported [17]. The
crystallized RVFV N protein validated that N protein has a
compact helical fold consisting of N-terminal and C-terminal lobes
of approximately equal size, and the N terminal residues (Tyr4,
Figure 4. Epitope mapping of SFTSV N protein by 3D structure prediction. Critical amino acids for antibody binding are indicated in the
modelling structure as the sites they located (Yellow). B) Ramachandran plot of the N protein prediction illustrates that visualized backbone dihedral
angles (phi/psi) of amino acid residues in modeling structure are properly validate.
doi:10.1371/journal.pone.0038291.g004
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bic residues to stabilize the hydrophobic core of the N protein
[16]. Therefore, the immunogenicity of N- and C- terminus of
SFTSV N protein might associate with their functions to impact
the oligomerization and stabilization of N protein.
In addition, according to the results of competition assay, at
least four distinct antigenic sites were recognized by MAbs,
represented by human MAbs H2A12, H2H9, and mouse M3E11,
M1D8. Mutation analysis revealed critical amino acid residues for
binding with MAbs H2A12 group, M1D8, M3E11, however, the
binding sites of H2H9 still remain unclear. Although interface of
antigen and antibody is best defined by crystallography, computer-
simulated modeling combined with site-directed mutagenesis has
been used successfully to define the sites critical for the interaction
between antibody and antigen [31]. We also performed the
synthesized peptide mapping which is commonly used for the
epitope mapping study, but our results were not productive
probably due to the inherent complexity of the viral antigen (Data
not shown). Using specific MAbs to analyze viral evolutions with
natural gene selection will give us more information on critical
epitope mapping of SFTS N protein, and this certainly requires
more investigation.
In summary, we generated and characterized a panel of human
MAbs against nucleocapsid protein of SFTS virus derived from
SFTSV infected patients using phage display technology. Impor-
tantly, localization of at least 4 antigenic sites on nucleocapsid
protein recognized by a panel of human MAbs has provided, for
the first time, insight into the human antibody responses to SFTS
viruses which contribute to the SFTS immunity in the recovered
patient. Furthermore, the critical role of N- terminal amino acids
for the immunogenicity of SFTSV N protein would help to
understand the significance of the defined epitopes and applica-
tions for diagnosis of human infection with SFTS virus.
Supporting Information
Figure S1 Characterization of mouse MAbs to glycoprotein Gn
and Gc by IFA. The antigen slides were made from Vero cells
infected with SFTSV strain HB29, or Sf9 cells expressing Gn or
Gc protein with infection of recombinant baculovirus. Mouse
MAbs represented by 2D5 showed Gn specificity on both Vero
and Sf9 cells (Vero-Gn, Sf9-Gn); mouse MAbs represented by
M1G8 showed Gc specificity on both Vero and Sf9 cells (Vero-Gc,
Sf9-Gc).
(TIF)
Figure S2 IFA and western blot assay of truncated N protein
from the 293T lysate with rabbit polyclonal antibody. The intact
N and truncated N proteins were transiently expressed in 293T
cells and the cells tested by IFA (A) with R. poly antibodies showed
a positive reactivity to the intact N and truncated gN5, and a
weak intensity of fluorescence to truncated gN10 and gC5
proteins. The cell lysates were used for western blot assay of above
truncated N protein and showed all positive reactivity (B). R. poly:
A rabbit polyclonal antibody immunized with the SFTSV N
protein; N: The intact N protein transiently expressed in293T
cells; gN5, gN10 and gC5: Truncation of 5, 10 amino acids at
the N- or C-terminus of N protein; NC: Normal 293T cells as
negative control.
(TIF)
Table S1 Neutralization activity of human and mouse MAbs
against SFTSV tested by micro-neutralization test.
(DOC)
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